Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program

BACKGROUND: Canagliflozin is approved for glucose lowering in type 2 diabetes and confers cardiovascular and renal benefits. We sought to assess whether it had benefits in people with chronic kidney disease, including those with an estimated glomerular filtration rate (eGFR) between 30 and 45 mL/min...

Descripción completa

Detalles Bibliográficos
Autores principales: Neuen, Brendon L., Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R., de Zeeuw, Dick, Mahaffey, Kenneth W., Fulcher, Greg, Desai, Mehul, Li, Qiang, Deng, Hsiaowei, Rosenthal, Norm, Jardine, Meg J., Bakris, George, Perkovic, Vlado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181277/
https://www.ncbi.nlm.nih.gov/pubmed/29941478
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181277/
https://www.ncbi.nlm.nih.gov/pubmed/29941478
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901

Ejemplares similares